Johnson Controls Reports Strong Start to Fiscal Year; Provides Fiscal 2021 Full Year and Q2 Guidance
- GAAP EPS of $0.45; Adjusted EPS of $0.43, up 8% versus prior year
- Continued sequential quarterly improvement in sales, orders and profitability
- Backlog of $9.5B increases 3% organically year-over-year
- Cash provided by operating activities was $0.5 billion; Free cash flow of $0.4 billion
- Executed $346 million of planned share repurchases in Q1
- Announced ambitious new ESG commitments
- Provides fiscal 2021 second quarter adjusted earnings per share guidance range of $0.47 to $0.49; top-line organic growth expected to turn positive
- Provides fiscal 2021 full year adjusted earnings per share guidance range of $2.45 to $2.55; represents a 9 to 14% increase year over year
WEC Energy Group raises quarterly dividend
News provided by
Share this article
Share this article
MILWAUKEE, Jan. 21, 2021 /PRNewswire/ The board of directors of WEC Energy Group (NYSE: WEC) today declared a quarterly cash dividend of 67.75 cents per share on the company s common stock, an increase of 7.1 percent over the current quarterly dividend of 63.25 cents a share. This raises the annual dividend rate to $2.71 a share.
The higher dividend is payable March 1, 2021, to stockholders of record on Feb. 14, 2021. This marks the 314
th consecutive quarter dating back to 1942 that the company will have paid a dividend to its stockholders. With today s action by our board, 2021 will be the eighteenth consecutive year of dividend increases for our stockholders, said Gale Klappa, executive chairman. We continue to target a dividend payout of 65 to 70 percent of earnings.
Sanofi: MHRA Grants Promising Innovative Medicine Designation to Nirsevimab
1,2
RSV is a contagious virus, and the most common cause of severe lower respiratory tract infections (LRTI) in infants and young children, resulting in over 30,000 hospitalisations per year in the UK due to RSV-associated LRTIs for children under five years
3
Promising Innovative Medicine (PIM) Designation was granted based on non-clinical and clinical data of nirsevimab in healthy preterm infants
Nirsevimab does not have a Marketing Authorisation (MA) in the UK for any indication
FOR MEDICAL AND PHARMACEUTICAL TRADE MEDIA ONLY
The Medicines and Healthcare Products Regulatory Agency (MHRA) has granted a Promising Innovative Medicine (PIM) Designation to nirsevimab, an extended half-life monoclonal antibody (mAb) being investigated as a passive immunisation for the prevention of lower respiratory tract infections (LRTI) caused by respiratory syncytial virus (RSV) in all infants in their first RSV se
Kenorland Extends Till Anomaly and Commences 3D IP Survey at Regnault
News provided by
Share this article
Kenorland Minerals Ltd. ( Kenorland or the Company ) is pleased to report additional geochemical sampling results, including fine-fraction geochemistry, gold grain counts, as well as boulder assays from the fall 2020 exploration program at the Regnault target within the Frotet Project (the Project ) located in the Frotet-Evans greenstone belt of Quebec. All samples were collected to the southwest of the Regnault Discovery Area where the company intersected 29.08m at 8.47g/t Au including 11.13m at 18.43g/t Au on the initial first pass drill program in early 2020 (see press release dated July 29, 2020). In addition, a 129 line-kilometer 3D induced polarization (IP) geophysical survey covering the entire five kilometer Regnault trend is currently underway.
Parkland Corporation Announces January 2021 Dividend
/EIN News/ CALGARY, Alberta, Jan. 13, 2021 (GLOBE NEWSWIRE) Parkland Corporation (“Parkland”) (TSX:PKI) announces that a dividend of $0.1012 per share will be paid on February 15, 2021 to shareholders of record on January 22, 2021. The dividend will be an eligible dividend for Canadian income tax purposes. The ex-dividend date is January 21, 2021.
Enhanced Dividend Reinvestment Plan
Parkland s enhanced Dividend Reinvestment Plan ( Enhanced DRIP ) allows shareholders to reinvest their cash dividends to purchase additional Parkland shares from treasury at a 5% per share discount to the average of the daily volume weighted average trading prices during the Pricing Period. For further details on the Enhanced DRIP and the Pricing Period, please visit www.parkland.ca/en/investors/dividends.